Lb-100

Lb-100

SCHEMBL12390164

CN1CCN(C(=O)[C@@H]2[C@H](C(=O)O)[C@H]3CC[C@@H]2O3)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPP2CAPPP2CBPPP5C

The experimentally established mechanism targets of Lb-100. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPP5C known ✓ P53041 2/20 1.00
PPP2CA known ✓ P67775 1/20 1.00
TFPI2 P48307 9/20 1.00
NPY4R P50391 1/20 1.00
KDM4E B2RXH2 1/20 0.57
GMNN O75496 1/20 0.57
LMNA P02545 1/20 0.57
PMP22 Q01453 1/20 0.57
TP53 P04637 1/20 0.57
TSHR P16473 1/20 0.57
NFKB1 P19838 1/20 0.57
THPO P40225 1/20 0.57
PPM1B O75688 3/20 0.49
PTPN1 P18031 3/20 0.49
PPP1CC P36873 2/20 0.49
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lb-100 SCHEMBL19501013 1.00 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RKDM4E
Lb-100 SCHEMBL2832350 1.00 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RKDM4E
Lb-100 SCHEMBL26377801 1.00 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RKDM4E
Lb-100 SCHEMBL19512780 1.00 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RKDM4E
Lb-100 SCHEMBL13311584 1.00 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RKDM4E
Lb-100 SCHEMBL9880148 1.00 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RKDM4E
SCHEMBL14135374 0.87 TFPI2 (0.77) TFPI2PPP5CPPP2CANPY4RKDM4E
SCHEMBL2332631 0.86 TFPI2 (0.77) TFPI2PPP5CPPP2CANPY4RKDM4E
SCHEMBL1572846 0.85 TFPI2 (0.74) TFPI2PPP5CPPP2CANPY4RKDM4E
SCHEMBL12390209 0.85 TFPI2 (0.74) TFPI2PPP5CPPP2CANPY4RKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310418-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER LIXTE BIOTECHNOLOGY, INC. 2023-10-05 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-9994584-B2 Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid LIXTE BIOTECHNOLOGY, INC. (US) 2018-06-12 US disclosed
US-9994584-B2 Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid LIXTE BIOTECHNOLOGY, INC. (US) 2018-06-12 US disclosed
US-9988394-B2 Oxabicycloheptane prodrugs LIXTE BIOTECHNOLOGY INC. (US) 2018-06-05 US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 US disclosed
US-20170305925-A1 PROCESS OF SYNTHESIZING 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICYCLO[2.2.1] HEPTANE-2-CARBOXYLIC ACID LIXTE BIOTECHNOLOGY, INC. (US) 2017-10-26 US disclosed
WO-2016186963-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. (US) 2016-11-24 WO disclosed
US-20160333024-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. (US) 2016-11-17 US disclosed
US-20160333024-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. (US) 2016-11-17 US disclosed
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. 2015-02-12 US disclosed
US-8822461-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2014-09-02 US disclosed
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2013-11-14 US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
WO-2008097561-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305925-A1 PROCESS OF SYNTHESIZING 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICYCLO[2.2.1] HEPTANE-2-CARBOXYLIC ACID DHPS, CYP1B1, CYP4Z1 PPP5C 258/4885PPP2CA 108/4885TFPI2 2205/4885
US-20230310418-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER BCL3, BCL2L10, BIRC3 PPP5C 1024/4885PPP2CA 2291/4885TFPI2 2757/4885
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC PPP5C 3037/4885PPP2CA 2107/4885TFPI2 4858/4885
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC PPP5C 3037/4885PPP2CA 2107/4885TFPI2 4858/4885
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC PPP5C 3037/4885PPP2CA 2107/4885TFPI2 4858/4885
US-20160333024-A1 OXABICYCLOHEPTANE PRODRUGS UGT2B7, UGT1A6, UGT1A1 PPP5C 1743/4885PPP2CA 608/4885TFPI2 4843/4885
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use HCCS, VHL, OXA1L PPP5C 2860/4885PPP2CA 2048/4885TFPI2 4843/4885
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC PPP5C 3037/4885PPP2CA 2107/4885TFPI2 4858/4885
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC PPP5C 3037/4885PPP2CA 2107/4885TFPI2 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.